At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 427 enrolled

Drug / intervention

Neladenoson bialanate (BAY1067197) +5 moredrug

Likely dose

Neladenoson bialanate (BAY1067197) 5 mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02992288

NCT02992288Phase 2Completed

Compare CT.gov

A Multicenter, Randomized, Placebo-controlled, Parallel Group, Double Blind, Dose-finding Phase II Trial to Study the Efficacy, Safety, Pharmacokinetic and Pharmacodynamic Effects of the Oral Partial Adenosine A1 Receptor Agonist Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction

Bayer·interventional·Posted Dec 14, 2016·Updated Apr 23, 2019

In Brief

A Phase 2 clinical trial evaluating Neladenoson bialanate (BAY1067197) and Placebo for Heart Failure. Completed, enrolled 427 participants across 75 sites in 11 countries.

Detailed Summary

The objective of the study is to find the optimal dose of once daily oral neladenoson bialanate (BAY 1067197) when given in addition to standard therapy for heart failure with reduced ejection fraction (HFrEF).

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsHeart Failure

CountriesBelgium, Bulgaria, Germany, Greece, Israel, Italy, Japan, Netherlands, Poland, Spain, United States

Collaborators--

Timeline

Phase 2CompletedFinished

2017201820192020202120222023202420252026

First PostedDec 2016

Enrollment StartFeb 2017

Primary CompletionMar 2018

Study CompletionMay 2018

TodayJul 2026

First PostedDec 14, 2016

Enrollment StartFeb 22, 2017

Primary CompletionMar 28, 2018

Study CompletionMay 16, 2018

TodayJul 2, 2026

Enrollment to primary: 1.1 yearsPosted 9.5 years ago